Trials / Completed
CompletedNCT02141438
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,472 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 dichloride (Xofigo, BAY88-8223) | This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information. |
Timeline
- Start date
- 2014-08-20
- Primary completion
- 2024-08-02
- Completion
- 2024-10-24
- First posted
- 2014-05-19
- Last updated
- 2025-10-16
- Results posted
- 2025-09-05
Locations
68 sites across 20 countries: United States, Argentina, Austria, Belgium, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Luxembourg, Mexico, Netherlands, Portugal, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02141438. Inclusion in this directory is not an endorsement.